FindTrial
Sign In

A real-world study on the use of Senaparib for first-line maintenance treatment of newly diagnosed BRCAwt advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer

A real-world study on the use of Senaparib for first-line maintenance treatment of newly diagnosed BRCAwt advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117526
Enrollment
Unknown
Registered
2026-01-26
Start date
2026-01-31
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer

Interventions

Senaparib Group:NA

Sponsors

The Second Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients newly diagnosed with advanced ovarian cancer, primary peritoneal cancer or fallopian tube cancer of BRCAwt type; 2. Age >= 18 years old; 3. The investigators assess that the Senaparil regimen can be used for treatment; 4. Patients voluntarily participate in this study;

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women confirmed; 2.Other situations judged by the researchers as not suitable for inclusion in the study;

Design outcomes

Primary

MeasureTime frame
Safety;—

Secondary

MeasureTime frame
Progression-free survival;Overall Survival;—

Countries

China

Contacts

Public ContactJianwei Zhou

The Second Affiliated Hospital of Zhejiang University School of Medicine

jianwei-zhou@163.com+86 571 89713631

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026